Treatment in accordance with NICE guidelines and criteria.

For oncological treatment, or for immunological therapy by those experienced.

For use in Gastroenterology, azathioprine is SC in the Black Country formulary, i.e. for prescribing in primary care under a shared care agreement.

This is commssioned by NHSE for the indications below and a Blueteq form must be completed before prescribing. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

Any other use is non-formulary and the non-formulary request process should be followed. 

Active autoantibody-positive systemic lupus erythematous.

This is Red in the Black Country IMOC formulary, i.e for hospital prescribing only.

This is commssioned by NHSE for the indications below and a Blueteq form must be completed before prescribing. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

Any other use is non-formulary and the non-formulary request process should be followed. 

Periodic fevers and autoinflammatory diseases

For malaria this is Black in the Black Country IMOC formulary for prophylaxis, but can be supplied on a private prescription. For all other uses it is Green.

For transplant rejection or licensed uses by dermatology, ophthalmology, and rheumatology consultants - all other use requires the approval of the FTG.
Refractory Ulcerative Colitis.

This is SC in the Black Country IMOC formulary, i.e. it can be prescribed in primary care on the completion of the RMOC ESCA. Please prescribe by brand.

This is SC in the Black Country IMOC formulary, i.e. it can be prescribed in primary care on the completion of the RMOC ESCA.

For transplant rejection, treatment of SLE by Consultant Rheumaotlogists according to protocol, or other uses agreed by FTG.

This is SC in the Black Country IMOC formulary, i.e. it can be prescribed in primary care on the completion of the RMOC ESCA.

Drug Safety Update Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis

This is commissioned by NHSE

1. for the treatment of ANCA-associated vasculitis in adults, or

2. for refractory Systemic Lupus Erythematosus (SLE) in Adults and children, or 

3. for adult and post-pubescent patients for the prevention of Delayed Haemolytic Transfusion Reactions and Hyperhaemolysis in patients with haemoglobinopathies, or 

4. for the treatment of immunobullous disease in adults and children with pemphigoid (as 4th line treatment), or 

5. for the treatment of immunobullous disease in adults and children with pemphigus (as 3rd line treatment), or

6. in combination with venetoclax for the treatment of previously treated chronic lymphatic leukaemia

and a Blueteq form must be completed before prescribing. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

All other indications are ICB commissioned and a Blueteq form is required before prescribing, if available.

This is Red in the Black Country IMOC formulary, i.e for hospital prescribing only.

See this safety information from the MHRA.

This is commissioned by NHSE and a Blueteq form must be completed before prescribing. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

This is commssioned by NHSE for the indications below and a Blueteq form must be completed before prescribing. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

Any other use is non-formulary and the non-formulary request process should be followed. 

Multiple Sclerosis relapsing–remitting in adults and children

This is commssioned by NHSE for the indications below and a Blueteq form must be completed before prescribing. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

Treatment of highly active relapsing remitting multiple sclerosis after 1st line treatment in children

Treatment of rapidly evolving severe (RES) relapsing-remitting multiple sclerosis after natalizumab treatment in children

Treatment of rapidly evolving severe (RES) relapsing-remitting multiple sclerosis after natalizumab treatmen